Abstract
Mycobacterium tuberculosis is the causative agent of tuberculosis, a lethal infection disease that attacks the lungs. Now it becomes the major global health risk because of very long latent period, the persistent increase of new cases, and the emergence of multidrug-resistant and extensively drug-resistant strains. Therefore, there is an urgent need for the development of new, safe and more efficient tuberculosis drugs. The shikimate pathway has been considered as the attractive drug target due to its essentiality in algae, higher plants, bacteria, and fungi, but absence from mammals. In this review, we focus on the recent development of a wide variety of inhibitors of type II Mycobacterium tuberculosis dehydroquinate dehydratase, the third enzyme of this pathway. The structural and mechanistic features of the enzyme for the design and discovery of the inhibitors have been described. The key factors on the structure, binding, and affinity of the inhibitors have been also highlighted. This may direct the further development of type II Mycobacterium tuberculosis dehydroquinate dehydratase inhibitors as potent tuberculosis drugs.
Keywords: Binding affinity, dehydroquinate dehydratase, drug design and discovery, inhibitor, Mycobacterium tuberculosis, tuberculosis.
Current Topics in Medicinal Chemistry
Title:Structure-and-Mechanism-Based Design and Discovery of Type II Mycobacterium Tuberculosis Dehydroquinate Dehydratase Inhibitors
Volume: 14 Issue: 1
Author(s): Yuan Yao and Li Ze-Sheng
Affiliation:
Keywords: Binding affinity, dehydroquinate dehydratase, drug design and discovery, inhibitor, Mycobacterium tuberculosis, tuberculosis.
Abstract: Mycobacterium tuberculosis is the causative agent of tuberculosis, a lethal infection disease that attacks the lungs. Now it becomes the major global health risk because of very long latent period, the persistent increase of new cases, and the emergence of multidrug-resistant and extensively drug-resistant strains. Therefore, there is an urgent need for the development of new, safe and more efficient tuberculosis drugs. The shikimate pathway has been considered as the attractive drug target due to its essentiality in algae, higher plants, bacteria, and fungi, but absence from mammals. In this review, we focus on the recent development of a wide variety of inhibitors of type II Mycobacterium tuberculosis dehydroquinate dehydratase, the third enzyme of this pathway. The structural and mechanistic features of the enzyme for the design and discovery of the inhibitors have been described. The key factors on the structure, binding, and affinity of the inhibitors have been also highlighted. This may direct the further development of type II Mycobacterium tuberculosis dehydroquinate dehydratase inhibitors as potent tuberculosis drugs.
Export Options
About this article
Cite this article as:
Yao Yuan and Ze-Sheng Li, Structure-and-Mechanism-Based Design and Discovery of Type II Mycobacterium Tuberculosis Dehydroquinate Dehydratase Inhibitors, Current Topics in Medicinal Chemistry 2014; 14 (1) . https://dx.doi.org/10.2174/1568026613666131113150257
DOI https://dx.doi.org/10.2174/1568026613666131113150257 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Screening of Few Epoxides as mt-MAPK Inhibitor Preventing Granuloma Formation to Serve as Tubercular Antidote
Letters in Drug Design & Discovery Modification Strategies of Lipid-Based Nanocarriers for Mucosal Drug Delivery
Current Pharmaceutical Design Exosomal MicroRNA: Diagnostic Marker and Therapeutic Tool for Lung Diseases
Current Pharmaceutical Design Behcets Syndrome: Literature Review
Current Rheumatology Reviews Predictive In Vitro Models of the Sterilizing Activity of Anti-Tuberculosis Drugs
Current Pharmaceutical Design Nutrition in Infancy
Current Pediatric Reviews High Throughput Screening of 7-Methylpicene-1,2-Diol as Arylamine N-Acetyltransferase (NAT) Inhibitor to Establish a Isoniazid Supplement in Anti-Tubercular Therapy
Combinatorial Chemistry & High Throughput Screening Focus on Pleiotropic Role of HMGB1 in the Onset of Allergic and Non- Allergic Respiratory Diseases
Current Respiratory Medicine Reviews Structure-Based Drug Discovery Accelerated by Many-Core Devices
Current Drug Targets Vitamin D and Sepsis: From Associations to Causal Connections
Inflammation & Allergy - Drug Targets (Discontinued) Isoniazid is Not a Lead Compound for its Pyridyl Ring Derivatives,Isonicotinoyl Amides, Hydrazides, and Hydrazones: A Critical Review
Current Medicinal Chemistry The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Drug Resistance Mutations from Whole Blood Proviral DNA Among Patients on Antiretroviral Drugs in Zimbabwe
Current HIV Research Drug Resistance of Antitubercular Agents at the Genetic Level in Mycobacterium Species: A Road Map to Drug Development for Counteracting the Resistance
Mini-Reviews in Organic Chemistry Clinical Development of Cationic Antimicrobial Peptides: From Natural to Novel Antibiotics
Current Drug Targets - Infectious Disorders A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections
Current Pharmaceutical Design Clostridium difficile Infection in Children with Inflammatory Bowel Disease: Current Evidence
Current Pharmaceutical Design Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry Ester of Quinoxaline-7-carboxylate 1,4-di-N-oxide as Apoptosis Inductors in K-562 Cell Line: An in vitro, QSAR and DFT Study
Anti-Cancer Agents in Medicinal Chemistry Current Tools and Methods in Molecular Dynamics (MD) Simulations for Drug Design
Current Medicinal Chemistry